TNF and rheumatoid arthritis: Gottenberg et al., in a study including 300 patients with RA that presented insufficient response to a first anti-TNF (persistent DAS ≥ 3.2), observed, after randomly switching to a second TNF or non-TNF biologic that more patients in the non-TNF group showed low disease activity compared with a second anti-TNF at 24 weeks (45 vs 28%; p = 0.004) and 52 weeks (41 vs 23%; p = 0.003).